New pill takes aim at Hard-to-Treat cancers

NCT ID NCT05867251

Recruiting now Disease control Sponsor: Avenzo Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is the first to test AVZO-021, an oral drug that blocks a protein called CDK2, in people with advanced solid tumors. The trial will enroll about 430 adults with certain breast, ovarian, or other cancers. The goal is to find safe doses and see if the drug can shrink tumors, both alone and with other cancer drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AVZO-021 (an oral CDK2 inhibitor)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that depend on CDK2, especially certain breast and ovarian cancers.
What could go wrong: This is a very early first-in-human study, so safety and effectiveness are not yet known. The drug may not work or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm Carcinoma, Ovarian Epithelial endometrial cancer endometrial carcinoma endometrium neoplasm fallopian tube cancer fallopian tube neoplasm hormone receptor-positive breast cancer neoplasm ovarian carcinoma primary peritoneal carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR CCNE1 AMPLIFICATION ENDOMETRIAL CANCER EPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CANCER HR+, HER2-, ADVANCED BREAST CANCER HR+/HER2- BREAST CANCER PRIMARY PERITONEAL CANCER TNBC - TRIPLE-NEGATIVE BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Cancer Care Wollongong
RECRUITING

Wollongong, New South Wales, Australia
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
Macquarie University Hospital
RECRUITING

Macquarie University, New South Wales, Australia
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
NYU Langone Medical Center (Tisch Hospital)
RECRUITING

New York, New York, 10016, United States
Oklahoma University
RECRUITING

Oklahoma City, Oklahoma, 73117, United States
Perlmutter Cancer Center at NYU Langone Hospital - Long Island
RECRUITING

Mineola, New York, 11501, United States
Providence Cancer Institute
RECRUITING

Portland, Oregon, 97213, United States
Sidney Kimmel Cancer Center (SKCC) at Jefferson Health
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Texas Oncology - DFW
RECRUITING

Dallas, Texas, 75246, United States
University Hospitals Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States
Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.